JGC
ADAP

J. Goldman & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

J. Goldman & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-311,153
Closed -$3.12M – 300
2020
Q2 		$3.12M Buy
+311,153
New +$1.95M 0.19% 129

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

J. Goldman & Co's ADAP Position: Q3 2020 in Review

J. Goldman & Co sold out of Adaptimmune Therapeutics (ADAP) in Q3 2020, closing a stake of 311,153 shares — an estimated $3.12M sold.

J. Goldman & Co first reported a position in ADAP in Q2 2020 and held it in 1 quarter. The position peaked at $3.12M in Q2 2020. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2020.

  • J. Goldman & Co reported no remaining Adaptimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • J. Goldman & Co sold 311,153 Adaptimmune Therapeutics shares in Q3 2020, an estimated $3.12M.
  • J. Goldman & Co first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 1 quarter.
  • J. Goldman & Co's Adaptimmune Therapeutics position peaked at $3.12M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2020.

Based on J. Goldman & Co's 13F filing for Q3 2020, filed 16 Nov 2020.